FDA Brief

Warning letters Drugs

FDA warning letter to

Lovely Meds, Inc. dba Lovely Meds

LowIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA cited Lovely Meds for misleading website claims that compounded semaglutide and tirzepatide are the same as FDA-approved drugs.

What happened

In August 2025, FDA reviewed the website lovelymeds.com and found it offers compounded semaglutide and tirzepatide products. FDA said the site’s claims “Same active ingredient as Wegovy and Ozempic” and “Same active ingredient as Zepbound & Mounjaro” are false or misleading because compounded drugs are not FDA-approved.

What FDA found

  1. The website claim that compounded semaglutide has the “same active ingredient” as Wegovy and Ozempic is false or misleading, making the product misbranded (false or misleading labeling).

    FDCA section 502(a) [21 U.S.C. § 352(a)]; section 502(bb) [21 U.S.C. § 352(bb)]
  2. The website claim that compounded tirzepatide has the “same active ingredient” as Zepbound and Mounjaro is false or misleading, making the product misbranded (false or misleading labeling).

    FDCA section 502(a) [21 U.S.C. § 352(a)]; section 502(bb) [21 U.S.C. § 352(bb)]
  3. FDA says the misbranded drugs were introduced or delivered for introduction into interstate commerce.

    FDCA section 301(a) [21 U.S.C. § 331(a)]
  4. FDA says receiving misbranded drugs in interstate commerce, and delivering or offering to deliver them, is also prohibited.

    FDCA section 301(c) [21 U.S.C. § 331(c)]

What FDA wants

FDA tells Lovely Meds to take immediate action, including stopping the cited language, and to send a written response within 15 working days to CDER’s Office of Compounding Quality and Compliance describing steps taken, documentation, and how it will prevent recurrence. If it disagrees or cannot finish, it must explain why and give a timeline.

Who should pay attention

  • telehealth companies selling compounded semaglutide or tirzepatide
  • compounders and pharmacies advertising GLP-1 products
  • marketing and compliance teams for online pharmacies

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  3. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  4. Buy Keta Online / www.buyketaonline.com

    FDA warns Buy Keta Online that its website sells unapproved and misbranded ketamine drugs to U.S. consumers.

    High risk